Involvement of TP53 in osteosarcoma - challenges and prospects

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Osteosarcoma (OS) is the most common primary bone cancer, characterized by high metastatic potential, chemoresistance, and poor prognosis.
• Mutations in the TP53 tumor suppressor gene are critical drivers of OS progression, affecting cell cycle, DNA repair, apoptosis, immune evasion, and metabolism.

Purpose of the Study:

• To provide an in-depth analysis of p53 biology in osteosarcoma.
• To highlight the impact of TP53 mutations on therapeutic resistance and tumor progression.
• To discuss novel therapeutic strategies targeting mutant TP53 and related pathways.

Main Methods:

• Comprehensive review of existing literature on p53 in osteosarcoma.
• Analysis of the role of TP53 mutations in OS pathogenesis.
• Exploration of current and emerging therapeutic approaches, including radiotherapy, chemotherapy, immunotherapy, metabolic reprogramming, noncoding RNA regulation, and precision biomarkers.

Main Results:

• TP53 mutations significantly influence OS progression and therapeutic response.
• Targeting mutant TP53 and its downstream pathways presents a promising therapeutic avenue.
• Emerging strategies like metabolic reprogramming and precision biomarkers show potential for improved diagnosis and treatment.

Conclusions:

• Understanding p53 biology is crucial for developing effective osteosarcoma treatments.
• Targeting mutant TP53 pathways and utilizing novel approaches can enhance therapeutic strategies.
• Translational research linking molecular mechanisms to clinical applications is key to improving outcomes for osteosarcoma patients.